Engineering manganese ferrite shell on iron oxide nanoparticles for enhanced T1 magnetic resonance imaging

• Published in: Journal of colloid and interface science 2022-11, Vol.626, p.364-373
• Main Authors: Li, Muyao, Bao, Jianfeng, Zeng, Jie, Huo, Linlin, Shan, Xinxin, Cheng, Xintong, Qiu, Dachuan, Miao, Wenjun, Zhu, Xianglong, Huang, Guoming, Ni, Kaiyuan, Zhao, Zhenghuan
• Format: Article
• Language: English
• Subjects: Iron oxide nanoparticles; Manganese ions; Surface optimization; T1 contrast agent
• ISSN: 0021-9797; 1095-7103
• DOI: 10.1016/j.jcis.2022.06.118

[Display omitted] Doping Mn (II) ions into iron oxide (IO) as manganese ferrite (MnIO) has been proved to be an effective strategy to improve T1 relaxivity of IO nanoparticle in recent years; however, the high T2 relaxivity of MnIO nanoparticle hampers its T1 contrast efficiency and remains a hurdle when developing contrast agent for early and accurate diagnosis. Herein, we engineered the interfacial structure of IO nanoparticle coated with manganese ferrite shell (IO@MnIO) with tunable thicknesses. The Mn-doped shell significantly improve the T1 contrast of IO nanoparticle, especially with the thickness of ∼0.8 nm. Compared to pristine IO nanoparticle, IO@MnIO nanoparticle with thickness of ∼0.8 nm exhibits nearly 2 times higher T1 relaxivity of 9.1 mM−1s−1 at 3 T magnetic field. Moreover, exclusive engineering the interfacial structure significantly lower the T2 enhancing effect caused by doped Mn (II) ions, which further limits the impairing of increased T2 relaxivity to T1 contrast imaging. IO@MnIO nanoparticles with different shell thicknesses reveal comparable T1 relaxation rates but obvious lower T2 relaxivities and r2/r1 ratios to MnIO nanoparticles with similar sizes. The desirable T1 contrast endows IO@MnIO nanoparticle to provide sufficient signal difference between normal and tumor tissue in vivo. This work provides a detailed instance of interfacial engineering to improve IO-based T1 contrast and a new guidance for designing effective high-performance T1 contrast agent for early cancer diagnosis.